Harvard Apparatus Regenerative Technology Inc · OTC:HRGN
Harvard Apparatus Regenerative Technology — Investor Presentation (September 2023)
19 slides from Harvard Apparatus Regenerative Technology's investor presentation, September 2023
Slide 1: Investor Presentation
Investor Presentation September 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements • This presentation contains forward-looking statements within the meaning of the federal securities laws. You can identify these statements by our use of such words as “before,” “track,” “will,” “should,” “could,” “anticipates,” “intends,” “guidance,” “objectives,” “optim
Slide 3: Executive Summary
Executive Summary • Clinical-stage regenerative medicine company focused on the repair and regeneration of organs damaged by cancer, trauma, birth defects and other diseases, using the patient’s own stem cells. • The world’s first successful regeneration of a human esophagus was completed at the May
Slide 4: Our Technology to Regenerate Organs
Our Technology to Regenerate Organs • Our technology uses a patient’s own stem cells that are grown on a hollow tubular scaffold to regenerate organ tissue damaged from cancer, trauma, birth defects or other diseases. • The patient’s stem cells stimulate the body’s natural regeneration process, and
Slide 5: The Huge Burden of Esophageal Cancer
The Huge Burden of Esophageal Cancer • The American Cancer Society estimates that there will be over 21,560 Americans diagnosed with esophageal cancer in 2023. There are over 600,000 worldwide. That’s one every minute. • It is estimated that 16,120 deaths (12,920 men and 3,200 women) from this disea
Slide 6: Surgical Treatment of Esophageal Cancer
Surgical Treatment of Esophageal Cancer • The current surgical treatment is removal of the diseased part of the esophagus, with the gap repaired by either a 1) gastric pull up, or 2) a colonic interposition. • Both procedures are difficult and expensive. “esophagectomy is a life-threatening procedur
Slide 7: Advantages of the HRGN Implant
Advantages of the HRGN Implant HRGN’s HRGN’s • Does not require the sacrifice of the patient’s stomach or colon. • Reduction of life-threatening complications associated with higher risk procedures. • Autologous stem cells eliminate the risk of immune system rejection. • Reduces the potential for lo
Slide 8: First in Human: Clinical Success in Esophageal Regeneration
First in Human: Clinical Success in Esophageal Regeneration • Surgery performed at Mayo Clinic by Dennis Wigle, MD, PhD - Chair of Thoracic Surgery. • The patient was 75-year-old man with cancer of the heart, lungs and esophagus. • The procedure was approved by the FDA under EIND (“compassionate use
Slide 9: Clinical Pathway
Clinical Pathway • Investigational New Drug application cleared by the FDA to commence a Phase 1 clinical trial. • Study led by Dennis Wigle, MD, PhD, Chair of Thoracic Surgery at Mayo Clinic. • The open-label trial will assess BOTH safety and efficacy in up to ten patients at five hospitals requiri
Slide 10: Pediatric Esophageal Atresia IND
Pediatric Esophageal Atresia IND • Once safety is established in esophageal implant clinical trials with adults, pediatric EA could be the next IND. • Esophageal atresia is a birth defect in which a part of newborn’s esophagus is not developed properly. • Researchers estimate 1 in every 2,500 to 4,0
Slide 11: Tremendous potential for a novel platform technology
Tremendous potential for a novel platform technology • Very promising HRGN’s regenerative technology can be applied to other organs, particularly other tubular organs. • Preliminary research studies have shown the regeneration of bronchus in large animals. One US patent on bronchus regeneration was
Slide 12: Large Global Markets
Large Global Markets Case Count By Geography Cancer Type USA China Worldwide Esophageal 18,309 324,422 604,100 Colon 101,809 306,078 1,148,515 Uterus （Asherman’s） 100,000* Breast 253,465 416,371 2,261,419 Liver 41,210 410,038 905,677 Source: World Cancer Research Fund International, National Library
Slide 13: Rejuvenate: Longevity Consumer Products in China
Rejuvenate: Longevity Consumer Products in China Market Size Longevity ⚫ In 2021, Chinese longevity market scale was US$10.89 billion[1] with a compound annual growth rate of 12.69% from 2018 to 2021. This market is expected to continue growing at a high rate in the future. ⚫ According to iiMedia Re
Slide 14: Rejuvenate: Longevity Consumer Products in Asia
Rejuvenate: Longevity Consumer Products in Asia Our Approach ⚫ Proven research or clinical data, with proven market demand in the US. ⚫ Introduce (OEM) High Quality American products (GMP, FDA registered, MADE in USA) to enter Asia market. ⚫ Strong scientific and quality brand --- Harvard Apparatus
Slide 15: Recent Developments
Recent Developments (in the last 6 months) ⚫04/06: raised 6 million USD in private placement ⚫05/31: Initiated clinical trial, details posted at clinicaltrials.gov ⚫07/18: Activated Mayo Clinic as our first clinical trial site ⚫07/20: Changed name back to Harvard Apparatus Regenerative Technology, I
Slide 16: Management & Board
Management & Board Management Board of Directors Jerry He – Chairman and CEO • Previously was the CEO of two NYSE listed companies, with extensive corporate management and capital market experience. Worked as management consultant for pharma Jason Chen and biotech companies. MS in Chemistry and MBA
Slide 17: Scientific & Clinical Advisory Board
Scientific & Clinical Advisory Board Stephen Badylak, DVM, Phd, Christine Finck, MD Charles Cox, MD MD (Chairman) • Deputy Director of the McGowan • Surgeon in Chief and Executive Vice • Director Pediatric Surgical Institute for Regenerative Medicine President at Connecticut Children’s Translational
Slide 18: Thanks
Rejuvenate · Regenerate Thanks
Slide 19: Appendix: Market Cap of Cell Therapy Companies
Appendix: Market Cap of Cell Therapy Companies Sep 01, 2023. $, Billions NASDAQ OTCQB NASDAQ NASDAQ NASDAQ NASDAQ NASDAQ $1.80 $1.60 $1.40 $1.20 $1.00 $0.80 $0.60 $0.40 $0.20 $- MIRO: HRGN: LCTX: HUMA: MESO: VCEL: ORGO: Before In Phase 1 In Phase 2 In Phase 3 Completed Marketing Marketing Clinical T
Harvard Apparatus Regenerative Technology — Investor Presentation (September 2023) on 6ix